Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

610.64
-14.9600-2.39%
Post-market: 610.640.00000.00%19:58 EDT
Volume:1.05M
Turnover:643.61M
Market Cap:66.76B
PE:15.93
High:628.00
Open:626.25
Low:607.88
Close:625.60
Loading ...

Company Profile

Company Name:
Regeneron Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1988
Employees:
15106
Office Location:
777 Old Saw Mill River Road,Tarrytown,New York,United States
Zip Code:
10591-6707
Fax:
- -
Introduction:
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Directors

Name
Position
Leonard S. Schleifer
Director, President and Chief Executive Officer
Arthur F. Ryan
Independent Director
Bonnie L. Bassler
Independent Director
Christine A. Poon
Independent Director
Craig B. Thompson
Independent Director
George D. Yancopoulos
President and Chief Scientific Officer,Director
George L. Sing
Independent Director
Huda Y. Zoghbi
Independent Director
Joseph L. Goldstein
Independent Director
Michael S. Brown
Independent Director
N. Anthony Coles
Independent Director
P. Roy Vagelos
Chair of the Board
David P. Schenkein
Director
Kathryn Guarini
Director

Shareholders

Name
Position
Leonard S. Schleifer
Director, President and Chief Executive Officer
Christopher Fenimore
Senior Vice President, Finance and Chief Financial Officer
Andrew J. Murphy
Executive Vice President, Research
Daniel P. Van Plew
Executive Vice President and General Manager, Industrial Operations and Product Supply
George D. Yancopoulos
President and Chief Scientific Officer,Director
Jason Pitofsky
Vice President, Controller
Joseph J. LaRosa
Executive Vice President, General Counsel and Secretary
Marion McCourt
Executive Vice President, Commercial
Neil Stahl
Executive Vice President, Research and Development